CTOs on the Move

Seneca Healthcare District

www.senecahospital.org

 
Seneca Healthcare District is a Chester, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Flyana.Com Inc

Flyana.Com Inc is a Anahola, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Priority Life Care

Priority Life Care, a family-owned company, was built on the thought that every senior deserves quality care regardless of their economic background. With over a decade of experience, the family has been a pioneer in the industry giving a win-win solution for both seniors and coworkers (the #PLCfamily). Our focus on senior living includes independent living, assisted living, and memory care. The key to our approach is in our purpose of supporting independence. In addition to care, our residents are able to continue living out their lives with healthy choices tailored to their individual needs.

Grane Rx

Grane Rx is a leader in long term care pharmacy solutions and services, supporting long term care communities and PACE providers. Grane Rx offers LTC pharmacy solutions and PACE pharmacy solutions for Pennsylvania, North Carolina, Massachusetts, New Je...

PurposeCare

PurposeCare is an integrated platform company that coordinates care in the community with a focus on individuals who are dually eligible for Medicaid and Medicare.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.